Sabrina McCrear

Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.

Real-world COPD data from ERS 2026 support RSV vaccination, but Jorgen Vestbo, MD, says cost remains the biggest barrier to wider uptake.

Timely dupilumab initiation after a severe asthma exacerbation lowered costs vs delayed treatment, ERS 2026 data show.

Jason Pogue, PharmD, breaks down which antibiotic classes carry the highest C. diff risk and why treatment duration matters just as much.

Francesca Polverino, MD, PhD, says COPD care still lacks a true precision medicine approach.

Keith Kaye, MD, MPH, breaks down the institutional gaps, from antibiotic overuse to hand hygiene fatigue, that let Clostridioides difficile persist.

A Danish cohort study found 100% RSV vaccine effectiveness in COPD, but Jorgen Vestbo, MD, urges caution interpreting real-world results.

Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.

Yet H. Khor, MD, PhD, explains why a 20% emphysema threshold on CT imaging may better define combined PF and emphysema in fibrotic ILD.

Laura Fabbri, MD, says patient wishes should guide care decisions in IPF and lung cancer overlap.

Francesca Polverino, MD, PhD, says COPD exacerbation severity lacks a clear definition, complicating GOLD's escalation criteria.

Yet H. Khor, MD, PhD, explains why the CPFE index can't replace CT imaging but may help triage which patients need scans.

Francesca Puggioni, MD, explains how real-world registry data, like the EU-ADVANTAGE study, informs regulatory decisions on asthma biologics.

Jorgen Vestbo, MD, on the COPERNICOS trial results, long-term antibiotic use versus resistance concerns, and where COPD treatment is headed.

Francesca Puggioni, MD, discusses real-world exacerbations, biomarker-driven access, and barriers to earlier biologic use in asthma and COPD.

Yet Khor discusses why a 20% CT emphysema threshold, not spirometry alone, best identifies CPFE and predicts outcomes in fibrotic ILD.

FDA approved zilganersen (ZANVASTRO), the first disease-modifying treatment for Alexander disease, based on pivotal trial data.

CMS awarded NY, RI, and MI Rural Health Transformation Program funding to expand rural health care workforce and technology access.

John R. Hurst, MD, PhD, explains how BEAM-302 gene editing targets both lung and liver disease in alpha-1 antitrypsin deficiency.

Francesca Puggioni, MD, explains how multidisciplinary teams choose COPD biologics and why systemic inflammation matters as much as FEV1.

Jorgen Vestbo, MD, discusses new COPERNICOS trial data showing patients who do not meet a specific eosinophil threshold can have inhaled ICS safely reduced.

Bioethicists say Kalshi's FDA and clinical trial betting markets risk bias, insider trading, and misleading signals about drug value.

Long-acting injectables help patients overcome stigma and adherence barriers in HIV care, explained Matthew H. Herrmann, MD, AAHIVS.

A researcher explains why cardiac diagnoses, not all-cause mortality, are the most reliable finding in her vaccine-safety study.

An infectious disease specialist discusses HIV prevention barriers facing Black women and how long-acting options and education can close gaps.

A cardiovascular researcher explains why her team compared cardiac risks of COVID-19 infection and vaccination head-to-head.

Experts discuss what SCAN Health Plan's new Medicare Advantage (MA) partnership with Costco could mean for beneficiaries, competition, and costs.

A Chest study of 1576 patients finds a 20% emphysema threshold best predicts survival and lung function decline in fibrotic ILD.

A 3-cohort study finds CC16 levels flag airway remodeling and fibrosis-like lung damage up to 3 years after severe COVID-19.

A 4-million-person study finds unvaccinated COVID-19 infection raises myocarditis, pericarditis, and death risk far more than the Pfizer vaccine.